Overall, the method of site-selective acylation and Fc conjugation to tune the basal-leaning pharmacology of insulin is described here the method of site-selective acylation and Fc conjugation to tune the basal-leaning pharmacology of insulin.
Abstract
Basal insulin therapy requires sustained and low-variability of insulin exposure; however, natural human insulin is rapidly cleared, thus necessitating frequent subcutaneous injections. Here we report a modular chemical platform for constructing monovalent insulin-Fc conjugates with structural homogeneity and long-term action. Site-selective acylation on three accessible amines of insulin (GlyA1, PheB1, or LysB29) yields a panel of alkynyl insulin analogs (3a-3c), which could couple with an azido Fc protein by CuAAC to produce monovalent insulin-Fc conjugates. Among these conjugates, Fc conjugation at LysB29 of insulin, namely 3c-Fc, retains the bioactivity, while insulin at GlyA1 (3a-Fc) and PheB1 (3b-Fc) were markedly deactivated, as assessed by the downstream Akt phosphorylation test. In vivo, the 3c-Fc conjugate exhibits a long pharmacokinetic and pharmacodynamic profile, which may result from the increase in the molecular size, the recycling by the neonatal Fc receptor, and the monovalence for slow insulin receptor-mediated clearance. Overall, we describe here the method of site-selective acylation and Fc conjugation to tune the basal-leaning pharmacology of insulin.
Commercialized designs of long-acting insulins often base their protracted mode of action on fatty acid acylation, which enables interaction between insulin and serum albumin. Building on that experience, we propose an alternative design where fatty acids are replaced with self-assembling, highly albumin-affine metal...
Jakub Cebula, Krzysztof Fink, W. Goldeman et al.· Bioconjugate chemistry· 1 citation
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapeutic agents for metabolic disease, whereas the pharmacological use of native GLP-1 is constrained by its extremely short circulating lifetime. Alb8-GA, a G-related albumin-binding domain, binds human serum albumin (HSA) with high affinity. Here...
M. Abolhassan, Zamara Mariam, Arpita Prasad et al.· International Journal of Bio...· 0 citations
Teriparatide, the only FDA-approved osteoanabolic drug for osteoporosis, suffers from poor metabolic stability and requires frequent subcutaneous injections, leading to suboptimal patient compliance. To find optimized teriparatide derivatives, we herein report an iterative peptide scanning strategy followed by a serine...
Bi-Yao Liu, Kai-Xuan Song, Hong-Li Sui et al.· Journal of Medicinal Chemist...· 0 citations
Compound 18f outperformed the antidiabetic effect of sitagliptin as the DPP-4 inhibitor in female Zucker Diabetic Fatty rats and underscores its potential as a promising lead compound for type 2 diabetes treatment.
Jaeki Min, Jihun Kim, Kyeongwon Moon et al.· Journal of Medicinal Chemist...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.